GlassScriptPhysician profile
Stephen M Johnson
NPI 1568751345
$2,436.98
in general payments reported to CMS, 2019-2025
21 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.95 · 2020: $59.24 · 2021: $486 · 2022: $543 · 2023: $437 · 2024: $528 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $810.00 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $426.28 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $200.68 | 2020-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.61 | 2021-2025 | Jardiance |
| Abbott Laboratories | $141.14 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $134.86 | 2021-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $83.14 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.17 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $57.36 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.39 | 2021-2025 | |
| Bausch Health US, LLC | $36.65 | 2021 | |
| Abbvie INC. | $35.85 | 2021-2023 | |
| Genzyme Corporation | $31.89 | 2025 | |
| Phathom Pharmaceuticals, INC. | $30.94 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $30.27 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $28.33 | 2022 | |
| Merck Sharp & Dohme LLC | $26.66 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.06 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $21.48 | 2025 | Symbravo |
| Csl Behring | $17.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.